
COVID-19 Diagnostics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Description
COVID-19 Diagnostics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of COVID-19 Diagnostics Market
The COVID-19 Diagnostics market size was valued at USD 46.76 billion in 2023, and the market is now projected to grow from USD 23.79 billion in 2024 to USD 8.91 billion by 2032, exhibiting a CAGR of -13.1% during the forecast period of 2024-2032.
With the expanding number of COVID-19 cases, need of nearness of any restorative or antibodies, and rise in government center on avoiding assist spread of COVID-19, an expanded request for time-efficient testing was observed with the advancements in COVID-19 diagnostics market growth. The sudden development of the COVID-19 emergency has caused an increment in its diagnostics exercises, treatment methods, and a rise in R&D exercises to create diagnostics, such as atomic tests and point of care tests. The developing request for COVID-19 diagnostics strategies and items has made monstrous openings within the healthcare industry thus increasing the showcase.
RT-PCR has been considered a standard test for COVID-19 determination due to its high precision, but it may take around 24 hours to induce the comes about. Be that as it may, at times, critical testing is required. Point of care/rapid COVID-19 diagnostics tests have played an imperative part in controlling the spread of the infection and encouraging the lifting of different limitations through an expanded number of every day tests.
Ensuring human lives is the foremost vital component of the healthcare framework amid a widespread circumstance. The expanding request for time-efficient and viable testing has driven pharmaceutical and restorative gadget companies to contribute in R&D to dispatch novel testing packs and measures. Expansive and little companies as well as new businesses are presenting items for patients and healthcare work force.
Comprehensive Analysis of COVID-19 Diagnostics Market
The bifurcation of product analysis is fractioned into two as reagents and kits and instruments. Enzyme-Linked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR) and Lateral Flow Immunoassay (LFIA) are the technology analysis of the COVID-19 diagnostics market wherein the PCR technology holds the largest share. On the reference of sample type, the market arena is fragmented into blood, oropharyngeal & nasopharyngeal swabs and nasal swabs. Delivering results within few hours, the swab test was figured as the dominant one. Point of care and lab-based were the two types of setting of the COVID-19 diagnostics market segmentation. The end-user analysis of the market is divided into home testing, hospital, clinics, laboratories and diagnostic centers.
The European continent with a higher valuation of USD 12.50 billion ruled the worldwide COVID-19 diagnostics market share in the projection of year 2021. The dominance of this region is due to the gigantic burden of COVID-19 cases in most European nations and expanded accentuation on more tests for controlling disease. New item dispatches within the Europe locale by major players too impelled the development of the advertise.
The advertise is exceedingly concentrated with different assortments of major players as: Abbott (U.S.), Quidel Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc., Danaher (U.S.), Quest Diagnostics Incorporated (U.S.), PerkinElmer Inc. (U.S.), Siemens Healthineers AG (Germany), bioMérieux SA (France) and many more.
In the month of December 2021, the Trusted Laboratory of DTPM reported that the FDA reissued the Tide Research facilities DTPM COVID-19 RT-PCR test crisis utilize authorization. With an alteration, the test will distinguish SARS-CoV-2 omicron variation.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2020-2029
Base Year 2021
Estimated Year 2022
Forecast Period 2022-2029
Historical Period 2020
Unit Value (USD billion)
Segmentation By Product
Instruments
Reagents & Kits
By Technology
Polymerase Chain Reaction (PCR)
Enzyme-Linked Immunosorbent Assay (ELISA)
Lateral Flow Immunoassay (LFIA)
Others
By Sample Type
Oropharyngeal & Nasopharyngeal Swabs
Nasal Swabs
Blood
By Setting
Lab-based
Point of Care
By End-user
Hospitals & Clinics
Laboratories & Diagnostic Centers
Home Testing
Others
By Geography
North America (U.S. and Canada)
Europe (Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe)
Asia Pacific (India, Japan, Australia, South Korea, and Rest of Asia Pacific)
Latin America (Brazil, Mexico, and Rest of Latin America)
Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
Table of Contents
194 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Overview: Guidelines of COVID-19 Diagnosis
- 4.2. New Product launches
- 4.3. Prevalence of COVID-19 Diseases
- 4.4. Number of Tests for 2020 & 2021
- 4.5. Impact of COVID-19 on Diagnostic Market
- 4.6. Overview of Regulatory Scenario
- 4.7. Impact on Supply Chain of Diagnostics Amid the Pandemic
- 4.8. Key Industry Developments
- 4.9. Recent Launches/Developments Pertaining to Mobile/On-site COVID-19 Testing
- 5. Global COVID-19 Diagnostics Market Analysis, Insights & Forecast, 2020-2029 - Scenario 1
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Product
- 5.2.1. Instruments
- 5.2.2. Reagents & Kits
- 5.3. Market Analysis, Insights and Forecast – By Technology
- 5.3.1. Polymerase Chain Reaction (PCR)
- 5.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 5.3.3. Lateral Flow Immunoassay (LFIA)
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast – By Sample Type
- 5.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 5.4.2. Nasal Swabs
- 5.4.3. Blood
- 5.4.4. Others
- 5.5. Market Analysis, Insights and Forecast – By Setting
- 5.5.1. Lab-based
- 5.5.2. Point of Care
- 5.6. Market Analysis, Insights and Forecast – By End user
- 5.6.1. Hospitals & Clinics
- 5.6.2. Laboratories & Diagnostic Centers
- 5.6.3. Home Testing
- 5.6.4. Others
- 5.7. Market Analysis, Insights and Forecast – By Region
- 5.7.1. North America
- 5.7.2. Europe
- 5.7.3. Asia Pacific
- 5.7.4. Latin America
- 5.7.5. Middle East & Africa
- 6. North America COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2020-2029 – Scenario 1
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Product
- 6.2.1. Instruments
- 6.2.2. Reagents & Kits
- 6.3. Market Analysis, Insights and Forecast – By Technology
- 6.3.1. Polymerase Chain Reaction (PCR)
- 6.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 6.3.3. Lateral Flow Immunoassay (LFIA)
- 6.3.4. Others
- 6.4. Market Analysis, Insights and Forecast – By Sample Type
- 6.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 6.4.2. Nasal Swabs
- 6.4.3. Blood
- 6.4.4. Others
- 6.5. Market Analysis, Insights and Forecast – By Setting
- 6.5.1. Lab-based
- 6.5.2. Point of Care
- 6.6. Market Analysis, Insights and Forecast – By End user
- 6.6.1. Hospitals & Clinics
- 6.6.2. Laboratories & Diagnostic Centers
- 6.6.3. Home Testing
- 6.6.4. Others
- 6.7. Market Analysis, Insights, and Forecast – By Country
- 6.7.1. U.S.
- 6.7.2. Canada
- 7. Europe COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2020-2029 – Scenario 1
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Product
- 7.2.1. Instruments
- 7.2.2. Reagents & Kits
- 7.3. Market Analysis, Insights and Forecast – By Technology
- 7.3.1. Polymerase Chain Reaction (PCR)
- 7.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 7.3.3. Lateral Flow Immunoassay (LFIA)
- 7.3.4. Others
- 7.4. Market Analysis, Insights and Forecast – By Sample Type
- 7.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 7.4.2. Nasal Swabs
- 7.4.3. Blood
- 7.4.4. Others
- 7.5. Market Analysis, Insights and Forecast – By Setting
- 7.5.1. Lab-based
- 7.5.2. Point of Care
- 7.6. Market Analysis, Insights and Forecast – By End user
- 7.6.1. Hospitals & Clinics
- 7.6.2. Laboratories & Diagnostic Centers
- 7.6.3. Home Testing
- 7.6.4. Others
- 7.7. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 7.7.1. Germany
- 7.7.2. U.K.
- 7.7.3. France
- 7.7.4. Italy
- 7.7.5. Spain
- 7.7.6. Russia
- 7.7.7. Rest of Europe
- 8. Asia Pacific COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2020-2029 – Scenario 1
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Product
- 8.2.1. Instruments
- 8.2.2. Reagents & Kits
- 8.3. Market Analysis, Insights and Forecast – By Technology
- 8.3.1. Polymerase Chain Reaction (PCR)
- 8.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 8.3.3. Lateral Flow Immunoassay (LFIA)
- 8.3.4. Others
- 8.4. Market Analysis, Insights and Forecast – By Sample Type
- 8.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 8.4.2. Nasal Swabs
- 8.4.3. Blood
- 8.4.4. Others
- 8.5. Market Analysis, Insights and Forecast – By Setting
- 8.5.1. Lab-based
- 8.5.2. Point of Care
- 8.6. Market Analysis, Insights and Forecast – By End user
- 8.6.1. Hospitals & Clinics
- 8.6.2. Laboratories & Diagnostic Centers
- 8.6.3. Home Testing
- 8.6.4. Others
- 8.7. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 8.7.1. Japan
- 8.7.2. India
- 8.7.3. Australia
- 8.7.4. South Korea
- 8.7.5. Rest of Asia Pacific
- 9. Latin America COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2020-2029 – Scenario 1
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Product
- 9.2.1. Instruments
- 9.2.2. Reagents & Kits
- 9.3. Market Analysis, Insights and Forecast – By Technology
- 9.3.1. Polymerase Chain Reaction (PCR)
- 9.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 9.3.3. Lateral Flow Immunoassay (LFIA)
- 9.3.4. Others
- 9.4. Market Analysis, Insights and Forecast – By Sample Type
- 9.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 9.4.2. Nasal Swabs
- 9.4.3. Blood
- 9.4.4. Others
- 9.5. Market Analysis, Insights and Forecast – By Setting
- 9.5.1. Lab-based
- 9.5.2. Point of Care
- 9.6. Market Analysis, Insights and Forecast – By End user
- 9.6.1. Hospitals & Clinics
- 9.6.2. Laboratories & Diagnostic Centers
- 9.6.3. Home Testing
- 9.6.4. Others
- 9.7. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 9.7.1. Brazil
- 9.7.2. Mexico
- 9.7.3. Rest of Latin America
- 10. Middle East & Africa COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2020-2029 – Scenario 1
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast – By Product
- 10.2.1. Instruments
- 10.2.2. Reagents & Kits
- 10.3. Market Analysis, Insights and Forecast – By Technology
- 10.3.1. Polymerase Chain Reaction (PCR)
- 10.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 10.3.3. Lateral Flow Immunoassay (LFIA)
- 10.3.4. Others
- 10.4. Market Analysis, Insights and Forecast – By Sample Type
- 10.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 10.4.2. Nasal Swabs
- 10.4.3. Blood
- 10.4.4. Others
- 10.5. Market Analysis, Insights and Forecast – By Setting
- 10.5.1. Lab-based
- 10.5.2. Point of Care
- 10.6. Market Analysis, Insights and Forecast – By End user
- 10.6.1. Hospitals & Clinics
- 10.6.2. Laboratories & Diagnostic Centers
- 10.6.3. Home Testing
- 10.6.4. Others
- 10.7. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 10.7.1. South Africa
- 10.7.2. GCC
- 10.7.3. Rest of Middle East & Africa
- 11. Global COVID-19 Diagnostics Market Analysis, Insights & Forecast, 2020-2029 - Scenario 2
- 11.1. Key Findings / Summary
- 11.2. Market Analysis, Insights and Forecast – By Product
- 11.2.1. Instruments
- 11.2.2. Reagents & Kits
- 11.3. Market Analysis, Insights and Forecast – By Technology
- 11.3.1. Polymerase Chain Reaction (PCR)
- 11.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 11.3.3. Lateral Flow Immunoassay (LFIA)
- 11.3.4. Others
- 11.4. Market Analysis, Insights and Forecast – By Sample Type
- 11.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 11.4.2. Nasal Swabs
- 11.4.3. Blood
- 11.4.4. Others
- 11.5. Market Analysis, Insights and Forecast – By Setting
- 11.5.1. Lab-based
- 11.5.2. Point of Care
- 11.6. Market Analysis, Insights and Forecast – By End user
- 11.6.1. Hospitals & Clinics
- 11.6.2. Laboratories & Diagnostic Centers
- 11.6.3. Home Testing
- 11.6.4. Others
- 11.7. Market Analysis, Insights and Forecast – By Region
- 11.7.1. North America
- 11.7.2. Europe
- 11.7.3. Asia Pacific
- 11.7.4. Latin America
- 11.7.5. Middle East & Africa
- 12. North America COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2020-2029 – Scenario 2
- 12.1. Key Findings / Summary
- 12.2. Market Analysis, Insights and Forecast – By Product
- 12.2.1. Instruments
- 12.2.2. Reagents & Kits
- 12.3. Market Analysis, Insights and Forecast – By Technology
- 12.3.1. Polymerase Chain Reaction (PCR)
- 12.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 12.3.3. Lateral Flow Immunoassay (LFIA)
- 12.3.4. Others
- 12.4. Market Analysis, Insights and Forecast – By Sample Type
- 12.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 12.4.2. Nasal Swabs
- 12.4.3. Blood
- 12.4.4. Others
- 12.5. Market Analysis, Insights and Forecast – By Setting
- 12.5.1. Lab-based
- 12.5.2. Point of Care
- 12.6. Market Analysis, Insights and Forecast – By End user
- 12.6.1. Hospitals & Clinics
- 12.6.2. Laboratories & Diagnostic Centers
- 12.6.3. Home Testing
- 12.6.4. Others
- 12.7. Market Analysis, Insights, and Forecast – By Country
- 12.7.1. U.S.
- 12.7.2. Canada
- 13. Europe COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2020-2029 – Scenario 2
- 13.1. Key Findings / Summary
- 13.2. Market Analysis, Insights and Forecast – By Product
- 13.2.1. Instruments
- 13.2.2. Reagents & Kits
- 13.3. Market Analysis, Insights and Forecast – By Technology
- 13.3.1. Polymerase Chain Reaction (PCR)
- 13.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 13.3.3. Lateral Flow Immunoassay (LFIA)
- 13.3.4. Others
- 13.4. Market Analysis, Insights and Forecast – By Sample Type
- 13.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 13.4.2. Nasal Swabs
- 13.4.3. Blood
- 13.4.4. Others
- 13.5. Market Analysis, Insights and Forecast – By Setting
- 13.5.1. Lab-based
- 13.5.2. Point of Care
- 13.6. Market Analysis, Insights and Forecast – By End user
- 13.6.1. Hospitals & Clinics
- 13.6.2. Laboratories & Diagnostic Centers
- 13.6.3. Home Testing
- 13.6.4. Others
- 13.7. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 13.7.1. Germany
- 13.7.2. U.K.
- 13.7.3. France
- 13.7.4. Italy
- 13.7.5. Spain
- 13.7.6. Russia
- 13.7.7. Rest of Europe
- 14. Asia Pacific COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2020-2029 – Scenario 2
- 14.1. Key Findings / Summary
- 14.2. Market Analysis, Insights and Forecast – By Product
- 14.2.1. Instruments
- 14.2.2. Reagents & Kits
- 14.3. Market Analysis, Insights and Forecast – By Technology
- 14.3.1. Polymerase Chain Reaction (PCR)
- 14.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 14.3.3. Lateral Flow Immunoassay (LFIA)
- 14.3.4. Others
- 14.4. Market Analysis, Insights and Forecast – By Sample Type
- 14.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 14.4.2. Nasal Swabs
- 14.4.3. Blood
- 14.4.4. Others
- 14.5. Market Analysis, Insights and Forecast – By Setting
- 14.5.1. Lab-based
- 14.5.2. Point of Care
- 14.6. Market Analysis, Insights and Forecast – By End user
- 14.6.1. Hospitals & Clinics
- 14.6.2. Laboratories & Diagnostic Centers
- 14.6.3. Home Testing
- 14.6.4. Others
- 14.7. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 14.7.1. Japan
- 14.7.2. India
- 14.7.3. Australia
- 14.7.4. South Korea
- 14.7.5. Rest of Asia Pacific
- 15. Latin America COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2020-2029 – Scenario 2
- 15.1. Key Findings / Summary
- 15.2. Market Analysis, Insights and Forecast – By Product
- 15.2.1. Instruments
- 15.2.2. Reagents & Kits
- 15.3. Market Analysis, Insights and Forecast – By Technology
- 15.3.1. Polymerase Chain Reaction (PCR)
- 15.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 15.3.3. Lateral Flow Immunoassay (LFIA)
- 15.3.4. Others
- 15.4. Market Analysis, Insights and Forecast – By Sample Type
- 15.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 15.4.2. Nasal Swabs
- 15.4.3. Blood
- 15.4.4. Others
- 15.5. Market Analysis, Insights and Forecast – By Setting
- 15.5.1. Lab-based
- 15.5.2. Point of Care
- 15.6. Market Analysis, Insights and Forecast – By End user
- 15.6.1. Hospitals & Clinics
- 15.6.2. Laboratories & Diagnostic Centers
- 15.6.3. Home Testing
- 15.6.4. Others
- 15.7. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 15.7.1. Brazil
- 15.7.2. Mexico
- 15.7.3. Rest of Latin America
- 16. Middle East & Africa COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2020-2029 – Scenario 2
- 16.1. Key Findings / Summary
- 16.2. Market Analysis, Insights and Forecast – By Product
- 16.2.1. Instruments
- 16.2.2. Reagents & Kits
- 16.3. Market Analysis, Insights and Forecast – By Technology
- 16.3.1. Polymerase Chain Reaction (PCR)
- 16.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 16.3.3. Lateral Flow Immunoassay (LFIA)
- 16.3.4. Others
- 16.4. Market Analysis, Insights and Forecast – By Sample Type
- 16.4.1. Oropharyngeal & Nasopharyngeal Swabs
- 16.4.2. Nasal Swabs
- 16.4.3. Blood
- 16.4.4. Others
- 16.5. Market Analysis, Insights and Forecast – By Setting
- 16.5.1. Lab-based
- 16.5.2. Point of Care
- 16.6. Market Analysis, Insights and Forecast – By End user
- 16.6.1. Hospitals & Clinics
- 16.6.2. Laboratories & Diagnostic Centers
- 16.6.3. Home Testing
- 16.6.4. Others
- 16.7. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 16.7.1. South Africa
- 16.7.2. GCC
- 16.7.3. Rest of Middle East & Africa
- 17. Competitive Analysis
- 17.1. Global Market Share Analysis (2021)
- 17.2. Company Profiles (Overview, Products, SWOT, Recent Developments, Strategies, Financials (based on availability))
- 17.2.1. F. Hoffmann-La Roche Ltd
- 17.2.1.1. Overview,
- 17.2.1.2. Products,
- 17.2.1.3. SWOT,
- 17.2.1.4. Recent Developments,
- 17.2.1.5. Strategies,
- 17.2.1.6. Financials (based on availability)
- 17.2.2. Abbott
- 17.2.2.1. Overview,
- 17.2.2.2. Products,
- 17.2.2.3. SWOT,
- 17.2.2.4. Recent Developments,
- 17.2.2.5. Strategies,
- 17.2.2.6. Financials (based on availability)
- 17.2.3. Danaher
- 17.2.3.1. Overview,
- 17.2.3.2. Products,
- 17.2.3.3. SWOT,
- 17.2.3.4. Recent Developments,
- 17.2.3.5. Strategies,
- 17.2.3.6. Financials (based on availability)
- 17.2.4. Siemens Healthineers AG
- 17.2.4.1. Overview,
- 17.2.4.2. Products,
- 17.2.4.3. SWOT,
- 17.2.4.4. Recent Developments,
- 17.2.4.5. Strategies,
- 17.2.4.6. Financials (based on availability)
- 17.2.5. Quidel Corporation
- 17.2.5.1. Overview,
- 17.2.5.2. Products,
- 17.2.5.3. SWOT,
- 17.2.5.4. Recent Developments,
- 17.2.5.5. Strategies,
- 17.2.5.6. Financials (based on availability)
- 17.2.6. bioMérieux SA
- 17.2.6.1. Overview,
- 17.2.6.2. Products,
- 17.2.6.3. SWOT,
- 17.2.6.4. Recent Developments,
- 17.2.6.5. Strategies,
- 17.2.6.6. Financials (based on availability)
- 17.2.7. Quest Diagnostics Incorporated
- 17.2.7.1. Overview,
- 17.2.7.2. Products,
- 17.2.7.3. SWOT,
- 17.2.7.4. Recent Developments,
- 17.2.7.5. Strategies,
- 17.2.7.6. Financials (based on availability)
- 17.2.8. Thermo Fisher Scientific Inc.
- 17.2.8.1. Overview,
- 17.2.8.2. Products,
- 17.2.8.3. SWOT,
- 17.2.8.4. Recent Developments,
- 17.2.8.5. Strategies,
- 17.2.8.6. Financials (based on availability)
- 17.2.9. PerkinElmer Inc.
- 17.2.9.1. Overview,
- 17.2.9.2. Products,
- 17.2.9.3. SWOT,
- 17.2.9.4. Recent Developments,
- 17.2.9.5. Strategies,
- 17.2.9.6. Financials (based on availability)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.